SCHEMBL23999524

SCHEMBL23999524

CC(=O)N(c1ccnc(C)c1)c1cnc2[nH]c(-c3ccc(Nc4ccnc5ccc(N(C)C)cc45)cn3)nc2c1

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 11/20 0.34
▸ EGFR P00533 3/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ GAA P10253 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ HTR2C P28335 1/20 0.33
▸ HTR2B P41595 1/20 0.33
▸ CYP2D6 P10635 1/20 0.32
▸ MAPKAPK2 P49137 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.30
▸ NPC1 O15118 1/20 0.30
▸ TP53 P04637 1/20 0.30
▸ HPGD P15428 1/20 0.30
▸ RAB9A P51151 1/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30
▸ HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26310194 0.91 KDR (0.41) KDREGFRALDH1A1GAAMAPT
SCHEMBL25495553 0.89 KDR (0.37) KDREGFRALDH1A1GAAMAPT
SCHEMBL23999823 0.87 MAPKAPK2 (0.36) MAPKAPK2
SCHEMBL23999835 0.85 SLC2A1 (0.41) GAAMAPTMAPK1TDP1L3MBTL1
SCHEMBL26310209 0.85 KDR (0.33) KDRMAPKAPK2
SCHEMBL23999476 0.84 KDR (0.39) KDREGFRMAPKAPK2
SCHEMBL30180227 0.84 KDR (0.39) KDREGFRMAPKAPK2
SCHEMBL25495945 0.79 EGFR (0.33) KDREGFR
SCHEMBL23999907 0.78 MAPKAPK2 (0.42) KDRMAPKAPK2
SCHEMBL23999676 0.78 KDR (0.42) KDRMAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295114-A1 AKT3 MODULATORS Georgiamune Inc. 2023-09-21 — — US disclosed
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 — — US disclosed
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 — — US disclosed
WO-2023081854-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2023-05-11 — — WO disclosed
WO-2021226517-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 — — WO disclosed
WO-2021226519-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295114-A1 AKT3 MODULATORS AKT3, AKT2, MTOR KDR 3433/4885EGFR 1297/4885ALDH1A1 4544/4885
US-20230183226-A1 AKT3 MODULATORS AKT3, AKT2, MTOR KDR 3271/4885EGFR 1128/4885ALDH1A1 4541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback